Anastrozole
Phase
Phase2Study status
CompletedView details
ARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
Next verified event · Clinical readout window
Announced Nov 3, 2026 · Announced window
Official announcement•Share additional monotherapy data from the ongoing Phase 1 dose escalation clinical trial in patients with B- and T-cell lymphomas (mid-2027).
Clinical readout window
Announced Nov 3, 2026 · Announced window
Official announcement•Share initial data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial (mid-2027).
Clinical readout window
Phase 1
NCT07749586Announced Nov 3, 2026 · Announced window
Official announcement•Present initial monotherapy data from the Phase 1 clinical trial (2H 2027).
9 programs · 5 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| ARVN ARVINAS, INC. | Anastrozole | Breast Cancer | Phase2 | Completed | Actual study completion2024-07-25 | NCT05549505 |
| ARVN ARVINAS, INC. | ARV-110 | Prostate Cancer Metastatic | Phase1 / Phase2 | Completed | Actual study completion2025-01-27 | NCT03888612 |
| ARVN ARVINAS, INC. | ARV-393 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase1 | Recruiting | NCT06393738 | |
| ARVN ARVINAS, INC. | ARV-471 | Breast Cancer | Phase2 | Completed | Actual study completion2024-07-25 | NCT05549505 |
| ARVN ARVINAS, INC. | ARV-6723 | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
| ARVN ARVINAS, INC. | ARV-806 | KRAS G12D Mutation; Advanced Solid Cancer | Phase1 / Phase2 | Active not recruiting | Estimated study completion2026-11-30 | NCT07023731 |
| ARVN ARVINAS, INC. | Glofitamab | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase1 | Recruiting | NCT06393738 | |
| ARVN ARVINAS, INC. | Pembrolizumab | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
| ARVN ARVINAS, INC. | SOC | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
Phase
Phase2Study status
CompletedARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Phase
Phase1 / Phase2Study status
CompletedARVINAS, INC.
IndicationProstate Cancer Metastatic
Actual study completion2025-01-27
Phase
Phase1Study status
RecruitingPhase
Phase2Study status
CompletedARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Phase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
Phase
Phase1 / Phase2Study status
Active not recruitingARVINAS, INC.
IndicationKRAS G12D Mutation; Advanced Solid Cancer
Estimated study completion2026-11-30
Phase
Phase1Study status
RecruitingPhase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
Phase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
22 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.